AcuityMD vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 52)
AcuityMD logo

AcuityMD

ChallengerHealthcare

AI-Powered MedTech Commercial Intelligence Platform

AcuityMD is the MedTech commercial intelligence platform trusted by nearly 500 companies including 8 of the top 10; raised $163M total including an $80M Series C; named to Forbes' 2025 Next Billion-Dollar Startups list;

AI VisibilityBeta
Overall Score
C52
Category Rank
#304 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
55
Perplexity
52
Gemini
49

About

AcuityMD is a Boston-based software company founded in 2018 that builds AI-powered commercial intelligence tools specifically for the medical technology (MedTech) industry. The platform provides medical device sales teams with a unified view of market data, physician and facility targeting, claims analytics, and CRM-integrated workflows — enabling them to identify the highest-value opportunities, forecast sales performance, and prioritize outreach with AI-generated next-best actions. AcuityMD draws on a dataset encompassing more than 330 million patients from an all-payor claims dataset built in partnership with CMS and major claims aggregators.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

52
Overall Score
90
#304
Category Rank
#2
78
AI Consensus
83
stable
Trend
stable
55
ChatGPT
92
52
Perplexity
93
49
Gemini
89
57
Claude
96
49
Grok
95

Key Details

Category
AI-Powered MedTech Commercial Intelligence Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.